Currently, the hope is that antibody cocktails specific to different neutralizing epitopes in the SARS-CoV-2 RBD, or other regions in the S protein of SARS-CoV-2, make effective COVID-19 treatments and provide short-term protection against viral infection. The gene discussed is PROS1; the disease is viral infectious disease.